Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Iterum Therapeutics plc Director's Dealing 2018

May 25, 2018

34796_dirs_2018-05-24_251ab832-11a1-4987-9908-9fcc3f514049.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2018-05-24

Reporting Person: Sofinnova Venture Partners IX, L.P. (10% Owner)
Reporting Person: POWELL MICHAEL (10% Owner)
Reporting Person: Sofinnova Management IX, L.L.C. (10% Owner)
Reporting Person: Mehra Anand (10% Owner)

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Series A Preferred Shares $ Ordinary Shares (721408) Direct
Series B-1 Preferred Shares $ Ordinary Shares (275446) Direct
Series B-2 Preferred Shares $ Ordinary Shares (229660) Direct

Footnotes

F1: The Series A Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder. The Series A Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2: Not applicable.

F3: The Series B-1 Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder. The Series B-1 Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4: The Series B-2 Preferred Shares are convertible into Ordinary Shares of the Issuer at the option of the holder. The Series B-2 Preferred Shares will automatically convert into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F5: The shares are held directly by Sofinnova Venture Partners IX, L.P. ("SVP IX"). Sofinnova Management IX, L.L.C. ("SM IX") is the general partner of SVP IX and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by SVP IX. Dr. James I. Healy, Michael F. Powell, Ph.D., and Dr. Anand Mehra are the managing members of SM IX and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by SVP IX. Each of the reporting persons disclaims beneficial ownership of such securities, except to the extent of his, her or its proportionate pecuniary interest therein.